Trials / Completed
CompletedNCT00470678
EXTEND III - Efficacy and Safety of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)
An Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Ranibizumab (0.5 mg) in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration Over 12 Months
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 95 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate efficacy and safety for monthly ranibizumab 0.5 mg intravitreal injections in Asian patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ranibizumab |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2008-11-01
- Completion
- 2008-11-01
- First posted
- 2007-05-08
- Last updated
- 2016-11-18
Locations
6 sites across 2 countries: South Korea, Taiwan
Source: ClinicalTrials.gov record NCT00470678. Inclusion in this directory is not an endorsement.